Outlook Therapeutics Financials - Benzinga

Outlook Therapeutics Inc

OTLKNASDAQ

Trade with Public

Trade with Public

$0.6531

0.02984.77%

Last update: Aug 27, 12:55 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Outlook Therapeutics Financials

Outlook Therapeutics (OTLK) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate

Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 79.55 percent increase over losses of $(0.44) per share from the same period last

Benzinga Newsdesk

S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone

CNN Fear & Greed index showed improved market sentiment, with S&P 500 hitting a new record high after PPI data release. Nasdaq up 0.81%.

Avi Kapoor

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.

Avi Kapoor

PRO
Outlook Therapeutics Q2 Adj. EPS $(0.16) Misses $(0.12) Estimate, Sales $128.000K Miss $4.400M Estimate

Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 60 percent increase over losses of $(0.40) per share

Benzinga Newsdesk

Outlook Therapeutics Earnings Report: Q1 Overview

Benzinga Insights

PRO
Outlook Therapeutics Q1 Adj. EPS $(0.22) Misses $(0.18) Estimate, Sales $(1.208M) Miss $5.025M Estimate

Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 75.28 percent increase over losses of $(0.89) per share

Benzinga Newsdesk